Home » clirophtha

Iris Pharma of France - Nice, a specialist contract research organisation (CRO) for pre-clinical research in ophthalmology, has announced the completion of its merger with Clirophtha, a unique CRO that is completely dedicated to ophthalmology services and clinical trials in Western Europe (Belgium, France, Germany, Italy, Portugal, Spain, Switzerland, United Kingdom), Eastern Europe (Bulgaria, Czech Republic, Poland, Roumania), North Africa (Tunisia, Morocco), Asia (Israel, India, Saudi Arabia, Turkey,) and North America (USA, Canada). The new entity born out the merger with Clirophtha will be known as Iris Pharma.

Clirophtha adds expertise and experience

The combined company (Clirophtha and Iris Pharma of France) will operate under the Iris Pharma name. This merger with Clirophtha establishes the first global drug-development services provider to be totally dedicated to ophthalmology, offering a complete range of services to biotechnology and pharmaceutical companies worldwide.

The cumulative expertise and experience from both Iris Pharma and Clirophtha guarantees that the new Iris Pharma company has an excellent know-how and extensive knowledge of each step in drug development, from pre-formulation and in vivo research to Phase IV and medico-marketing surveys, as well as a global overview of the whole process.